InflaRx N.V. IFRX
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +64.36%
- 1 year
- +25.76%
- Open
- 1.71
- Prev close
- 1.72
- Mkt cap
- 244.63M
- Vol
- 691.46K
- Avg vol
- 751.03K
- EPS
- -0.58
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.62
- High
- 1.71
- Forward P/E
- -2.36
- Beta
- 1.58
- Short ratio
- 5.17
- Inst. own
- 22.52%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 1.91
- 200-d avg
- 1.61
- 1y target
- 8.09
News
5 days ago globenewswire.com
InflaRx Announces November Investor Events
Jena, Germany, Oct. 27, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced…
1 week ago globenewswire.com
InflaRx Highlights Izicopan's Therapeutic Potential at Kidney Week 2026
Jena, Germany, Oct. 22, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced…
2 weeks ago defenseworld.net
InflaRx N.V. (NASDAQ:IFRX) Stock Has Average Target Price of $7.43
Shares of InflaRx N.V. (NASDAQ: IFRX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the nine brokerages that are covering the firm, MarketBeat reports. One…
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Profound Medical (NASDAQ:PROF) shares moved upwards by 21.5% to $6.9 during Thursday's pre-market session. The company's market cap stands at $207.5 million. Haemonetics (NYSE:HAE) stock…
1 month ago globenewswire.com
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
Jena, Germany, Oct. 02, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced…
1 month ago globenewswire.com
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
Jena, Germany, Oct. 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced…
1 month ago globenewswire.com
InflaRx to Host Virtual Capital Markets Day
Event to be hosted on November 3, 2026 at 8:00 AM EST Featured speakers will include Peter A. Merkel, MD, MPH and Prof.
1 month ago benzinga.com
This GE Vernova Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Analysts initiate: Sell GEV ($470); Buy IFRX ($8), LYNX ($21); Overweight FRSH ($18); Outperform NPWR ($2.75).
-
1 month ago benzinga.com
Needham Initiates Coverage On InflaRx with Buy Rating, Announces Price Target of $8
Needham analyst Joseph Stringer initiates coverage on InflaRx (NASDAQ:IFRX) with a Buy rating and announces Price Target of $8.
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Gelteq (NASDAQ:GELS) shares increased by 38.6% to $0.97 during Thursday's pre-market session. The company's market cap stands at $7.4 million. bioAffinity Technologies (NASDAQ:BIAF) shares…
2 months ago globenewswire.com
InflaRx Announces Participation in September Investor Conferences
Jena, Germany, Aug. 20, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced…
-
2 months ago benzinga.com
Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $6
Cantor Fitzgerald analyst Steve Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Overweight and raises the price target from $4 to $6.
-
2 months ago benzinga.com
InflaRx Q2 EPS $(0.10) Misses $(0.08) Estimate
InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.08) by 25 percent. This is a 58.33 percent increase over losses of $(0.24) per…
2 months ago globenewswire.com
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as planned Initiated feasibility assessment for broadened strategy for…
3 months ago globenewswire.com
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
Jena, Germany, July 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced…
3 months ago defenseworld.net
Reviewing InflaRx (NASDAQ:IFRX) and Kamada (NASDAQ:KMDA)
Kamada (NASDAQ: KMDA - Get Free Report) and InflaRx (NASDAQ: IFRX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses…
-
4 months ago benzinga.com
InflaRx Mulls Feasibility For AAV In Europe
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening…
4 months ago globenewswire.com
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced…
-
5 months ago benzinga.com
Raymond James Upgrades InflaRx to Strong Buy, Raises Price Target to $9
Raymond James analyst Ryan Deschner upgrades InflaRx (NASDAQ:IFRX) from Outperform to Strong Buy and raises the price target from $7 to $9.
-
5 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on InflaRx, Raises Price Target to $8
HC Wainwright & Co. analyst Matthew Keller maintains InflaRx (NASDAQ:IFRX) with a Buy and raises the price target from $6 to $8.
-
5 months ago benzinga.com
Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $4
Cantor Fitzgerald analyst Steve Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Overweight and raises the price target from $2 to $4.
5 months ago seekingalpha.com
InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript
InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
5 months ago marketbeat.com
InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline
InflaRx NASDAQ: IFRX outlined plans to prioritize development of izicopan, an oral inhibitor of the C5a receptor (C5aR), in ANCA-associated vasculitis (AAV) and other renal diseases during a company…
5 months ago globenewswire.com
InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
Jena, Germany, May 08, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system,…
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
5 months ago benzinga.com
InflaRx Prices Underwritten Offering of 75M Shares At $2.00 Per Share
All ordinary shares in the offering are being sold by the Company. The offering is expected to close on May 7, 2026, subject to the satisfaction of customary closing conditions.The Company intends to…
-
5 months ago benzinga.com
InflaRx Announces That It Intends To Develop Izicopan, An Oral C5A Receptor Inhibitor, In Life-Threatening Kidney Disorder AAV
InflaRx intends to develop izicopan in ANCA-associated vasculitis (AAV), with a secondary goal of establishing rapid proof of concept in additional life-threatening renal diseasesCapital Markets Day…
5 months ago globenewswire.com
InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares
Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system,…
5 months ago globenewswire.com
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced…
6 months ago globenewswire.com
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
JENA, Germany, May 04, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced…
6 months ago globenewswire.com
InflaRx to Report First Quarter 2026 Results on May 7, 2026
JENA, Germany, May 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced…
6 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
6 months ago benzinga.com
InflaRx Regains Nasdaq Compliance
InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company"), today announced that it has received a written…
6 months ago globenewswire.com
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
JENA, Germany, April 28, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the…
-
6 months ago benzinga.com
10 Health Care Stocks Moving In Friday's Intraday Session
10 Health Care Stocks Moving In Friday's Intraday Session
-
6 months ago benzinga.com
InflaRx Announces New In Vitro Findings Demonstrating That Izicopan Does Not Exhibit Time-Dependent Inhibition Of CYP3A4, Indicator For Risk For Ddis And Liver Toxicity
InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new in vitro findings demonstrating that izicopan…
6 months ago globenewswire.com
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
JENA, Germany, April 09, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today…
-
7 months ago benzinga.com
InflaRx Highlights Data From Phase 3 Study Of Vilobelimab In Pyoderma Gangrenosum At 2026 AAD Annual Meeting
InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the Phase 3 study of vilobelimab…
-
7 months ago benzinga.com
Guggenheim Maintains Buy on InflaRx, Lowers Price Target to $14
Guggenheim analyst Yatin Suneja maintains InflaRx (NASDAQ:IFRX) with a Buy and lowers the price target from $22 to $14.
-
7 months ago benzinga.com
InflaRx Q4 EPS $(0.17) Beats $(0.18) Estimate, Sales $(39.501K) Miss $230.000K Estimate
InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.18) by 5.56 percent. This is a 88.89 percent decrease over losses of $(0.09) per…
7 months ago benzinga.com
Earnings Scheduled For March 19, 2026
Earnings Scheduled For March 19, 2026
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
7 months ago benzinga.com
InflaRx Presents Oral Presentation At 2026 American Academy Of Dermatology Annual Meeting
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced an oral presentation during the Late-Breaking…
-
7 months ago benzinga.com
InflaRx Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it has received a written notice (the…
9 months ago benzinga.com
InflaRx Plans Workforce Reduction, Targets Mid-2027 Cash Runway
InflaRx outlines restructuring plans, workforce cuts, and reduced Gohibic spending to extend cash runway and focus development efforts on izicopan through mid-2027.
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
10 months ago benzinga.com
InflaRx Reopens Case For Axed Phase 3 Drug For Rare Skin Disorder
InflaRx presented data analyses from a terminated Phase 3 study on the potential treatment for rare skin condition.
-
10 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $6 Price Target
HC Wainwright & Co. analyst Matthew Keller reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $6 price target.
-
10 months ago benzinga.com
InflaRx Outlined Multiple Data Analyses Of The Phase 3 Study For Vilobelimab In Pyoderma Gangrenosum, Which Was Terminated Earlier In 2025 After An Independent Data Monitoring Committee Recommended To Stop The Trial Early Due To Futility
While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed),…